Reports Q2 revenue $631.9M, consensus $622.4M. “I’m pleased with our performance in the second quarter, with consolidated revenue and adjusted EBITDA both at the higher end of our guidance ranges. This reflects continued disciplined execution and builds on our solid results from the first quarter. We continue to work with focus and urgency to advance our strategic priorities, invest in products and capabilities, and deliver solid financial performance,” said Chuck Divita, CEO of Teladoc (TDOC) Health.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TDOC:
- Teladoc options imply 9.9% move in share price post-earnings
- Carvana upgraded, Ulta Beauty downgraded: Wall Street’s top analyst calls
- Teladoc initiated with a Neutral at Mizuho
- Teladoc’s Mixed Prospects: Hold Rating Amid Growth in Integrated Care and Challenges in BetterHelp Segment
- Options Volatility and Implied Earnings Moves Today, July 24, 2025